Biodelivery Sciences International Return on Equity

Biodelivery Sciences International (BDSI) currently reports a ROE of 45.18%. That is above the Healthcare sector average of 29.39%. Use the charts on this page to explore Biodelivery Sciences International's ROE history and peer comparisons.

Biodelivery Sciences International's ROE of 45.18% is higher than the Healthcare sector average of 29.39%. That is roughly 53.7% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Biodelivery Sciences International's current 45.18% should be judged against Healthcare norms (sector average: 29.39%) and against BDSI's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 45.18%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.39%. From there, open related valuation or income-statement pages for Biodelivery Sciences International, and consider following BDSI for alerts when major investors trade the stock.

Biodelivery Sciences International is classified in the Healthcare sector. On ROE, it currently shows 45.18% versus a sector average near 29.39%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BDSI with unrelated industries.